GlassScriptPhysician profile
Yevgeniy Veltman
NPI 1497917579
$11,554.42
in general payments reported to CMS, 2019-2025
41 companies · $2,250 in 2025
The $2,250 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $1,207 · 2021: $1,858 · 2022: $1,801 · 2023: $1,599 · 2024: $1,433 · 2025: $2,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,281.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $2,310.80 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $1,752.25 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Abbvie INC. | $1,096.55 | 2019-2025 | Lupron Depot, Botox |
| Boston Scientific Corporation | $958.76 | 2019-2025 | Ams 700 |
| Urovant Sciences INC | $872.39 | 2021-2022 | |
| Janssen Biotech, INC. | $689.27 | 2019-2025 | Erleada |
| Blue Earth Diagnostics | $420.22 | 2019-2025 | Posluma |
| Pfizer INC. | $380.78 | 2019-2025 | |
| Allergan, INC. | $326.07 | 2019-2022 | |
| Antares Pharma, INC. | $289.99 | 2021-2025 | Xyosted |
| Ferring Pharmaceuticals INC. | $250.37 | 2019-2025 | Adstiladrin |
| Neotract INC. | $215.45 | 2019-2020 | |
| Dornier Medtech America, INC | $204.57 | 2022 | |
| Dendreon Pharmaceuticals LLC | $140.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.82 | 2021-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevgeniy Veltman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.